Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone: Results from two placebo-controlled bipolar i maintenance studies

M. A. Frye, L. Yatham, T. A. Ketter, J. Goldberg, T. Suppes, J. R. Calabrese, C. L. Bowden, E. Bourne, R. S. Bahn, B. Adams

Resultado de la investigación: Articlerevisión exhaustiva

34 Citas (Scopus)

Resumen

Objective: To assess the relationship between depressive relapse and change in thyroid function in an exploratory post hoc analysis from a controlled maintenance evaluation of bipolar I disorder. Method: Mean thyroid-stimulating hormone (TSH) and outcome data were pooled from two 18-month, double-blind, placebo-controlled, maintenance studies of lamotrigine and lithium monotherapy. A post hoc analysis of 109 subjects (n = 55 lamotrigine, n = 32 lithium, n = 22 placebo) with serum TSH values at screening and either week 52 (±14 days) or study drop-out was conducted. Results: Lithium-treated subjects who required an intervention for a depressive episode had a significantly higher adjusted mean TSH level (4.4 μIU/ml) compared with lithium-treated subjects who did not require intervention for a depressive episode (2.4 μIU/ml). Conclusion: Lithium-related changes in thyroid function are clinically relevant and should be carefully monitored in the maintenance phase of bipolar disorder to maximize mood stability and minimize the risk of subsyndromal or syndromal depressive relapse.

Idioma originalEnglish (US)
Páginas (desde-hasta)10-13
Número de páginas4
PublicaciónActa Psychiatrica Scandinavica
Volumen120
N.º1
DOI
EstadoPublished - jul. 1 2009

ASJC Scopus subject areas

  • Psychiatry and Mental health

Huella

Profundice en los temas de investigación de 'Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone: Results from two placebo-controlled bipolar i maintenance studies'. En conjunto forman una huella única.

Citar esto